Trial Profile
A Phase IV, Single-arm, Open-label Study of Sorafenib (Nexavar) in Advanced Hepatocellular Carcinoma (HCC).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2013
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms HATT
- Sponsors Bayer
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 13 May 2013 Planned end date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.